Effect of tibolone on the survival of early stage cervical adenocarcinoma patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, S.-H. | - |
dc.contributor.author | Cho, Y.-J. | - |
dc.contributor.author | Cho, K.-J. | - |
dc.contributor.author | Ko, M.-H. | - |
dc.contributor.author | Jung, S.-Y. | - |
dc.contributor.author | Chon, S.-J. | - |
dc.contributor.author | Lim, S.-Y. | - |
dc.contributor.author | Lee, K.-B. | - |
dc.date.available | 2020-02-27T12:43:00Z | - |
dc.date.created | 2020-02-12 | - |
dc.date.issued | 2018-09 | - |
dc.identifier.issn | 2287-8572 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/4313 | - |
dc.description.abstract | Objective Gynecologic oncologists are uncertain about the safety of tibolone application in cervical adenocarcinoma (AC) patients. This study examined the possible adverse effects of tibolone on the survival of cervical AC patients. Methods Medical records of 70 cervical AC patients with International Federation of Gynecology and Obstetrics stages IA to IB were reviewed. A bilateral salpingo-oophorectomy was performed in all patients, and survival outcomes between tibolone users (n=38) and non-users (n=32) were compared. Results A comparison of the tibolone users with non-users revealed similar clinicopathological variables. Progression-free survival (P=0.34) and overall survival (P=0.22) were similar in the users and non-users. The risks of progression (hazard ratio [HR], 1.71; 95% confidence interval [CI], 0.46-6.37; P=0.43) and death (HR, 1.59; 95% CI, 0.06-45.66; P=0.79) were also similar in both groups. Conclusion Tibolone has no adverse effect on the survival of cervical AC patients and can be administered safely to this population. These findings may be helpful in improving the quality of life of cervical AC patients. © 2018 Korean Society of Obstetrics and Gynecology. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.language.iso | en | - |
dc.publisher | Korean Society of Obstetrics and Gynecology | - |
dc.relation.isPartOf | Obstetrics and Gynecology Science | - |
dc.title | Effect of tibolone on the survival of early stage cervical adenocarcinoma patients | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.doi | 10.5468/ogs.2018.61.5.584 | - |
dc.identifier.bibliographicCitation | Obstetrics and Gynecology Science, v.61, no.5, pp.584 - 589 | - |
dc.identifier.kciid | ART002384210 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85053238856 | - |
dc.citation.endPage | 589 | - |
dc.citation.startPage | 584 | - |
dc.citation.title | Obstetrics and Gynecology Science | - |
dc.citation.volume | 61 | - |
dc.citation.number | 5 | - |
dc.contributor.affiliatedAuthor | Lee, S.-H. | - |
dc.contributor.affiliatedAuthor | Cho, Y.-J. | - |
dc.contributor.affiliatedAuthor | Cho, K.-J. | - |
dc.contributor.affiliatedAuthor | Ko, M.-H. | - |
dc.contributor.affiliatedAuthor | Jung, S.-Y. | - |
dc.contributor.affiliatedAuthor | Chon, S.-J. | - |
dc.contributor.affiliatedAuthor | Lim, S.-Y. | - |
dc.contributor.affiliatedAuthor | Lee, K.-B. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Adenocarcinoma | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Survival | - |
dc.subject.keywordAuthor | Tibolone | - |
dc.subject.keywordAuthor | Uterine cervical neoplasm | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.